[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surgical-wound\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surgical-wound":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,37,63,91,119,151,186,208,235,262,285,306,332,367,394],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100560553","a-prospective-single-arm-clinical-trial-of-electrospun-fiber-matrix-restrata-in-the-treatment-of-surgical-defects-secondary-to-resection-of-malignant-cutaneous-neoplasms-100560553",false,"NCT06578650","A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms","Inclusion Criteria:\n\n1. Patient is at least 18 years old\n2. Patient plans to undergo surgical resection of a cutaneous neoplasm\n3. Patient is willing and capable of complying with all protocol requirements\n4. Patient or legally authorized representative (LAR) is willing to provide written informed consent prior to participation in study\n5. Post-resection surgical wound with a surface area of ≥4 cm2 and ≤ 36cm2\n\nExclusion Criteria:\n\n1. Inability to give informed consent or to complete the procedures required for study completion\n2. Patient has been previously enrolled into this study, or is currently participating in another drug or device study that has not reached its primary endpoint\n3. Patient is pregnant, breast feeding or planning to become pregnant\n4. Patient has a known allergy to resorbable suture materials, e.g. Polyglactin 910 (PGLA), Polydioxanone (PDS)\n5. Patients receiving any immunotherapy, radiation, or chemotherapy within the past four weeks prior to resection surgery.\n6. Patient has a life expectancy less than six months as assessed by the investigator\n7. Patient has an additional non-study related wound within 3 cm of the study wound\n8. Study wound is located on the hands or feet\n9. Patient has been diagnosed with osteomalacia\n10. Resection defect from a squamous cell carcinoma arising from a chronic wound\n11. Patient has an uncontrolled thyroid disorder\n12. Hgb A1c \\> 12% within 3 months prior to enrollment in patients with a known history of diabetes\n13. Patient has a BMI \\> 34.9\n14. Patient has used any tobacco product within the past 30 days prior to surgery\n15. Patients with chronic kidney disease on peritoneal or hemodialysis, or with an estimated glomerular filtration rate less than 15mL\u002Fmin\n16. Patients with severe liver disease with active cirrhosis defined as a gross ascites upon clinical exam or a Model for End-stage Liver Disease (MELD)-Na score greater than 15\n17. Patient not in reasonable metabolic control in the judgement of the investigator\n18. Patient has a known history of poor compliance with medical treatment\n19. Patient has a history of radiotherapy to wound bed of interest\n20. Patient has been diagnosed with at least one of the following autoimmune connective tissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoid arthritis\n21. Active infection, undrained abscess, or critical colonization of the wound with bacteria in the judgement of the investigator","ALL","18 Years",{"count":18,"type":19},34,"ESTIMATED","OBSERVATIONAL","The goal of this observational prospective study is to evaluate wound healing outcomes in resection wounds resulting from surgical removal of cutaneous malignancies treated with a synthetic electrospun fiber matrix. This study intends to quantify the time from initial resection and product application to time of complete granulation of the wound bed in weeks.",[23],"Surgical Wound","RECRUITING","2026-06-17",{"date":27,"type":28},"2026-06-18","ACTUAL",{"date":30,"type":28},"2024-10-31",{"date":32,"type":19},"2027-10",{"name":34,"class":35},"Acera Surgical, Inc.","INDUSTRY",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":36},"100517197","early-versus-delayed-bathing-of-orthopaedic-surgical-wounds-100517197","NCT06014411","Early Versus Delayed Bathing of Orthopaedic Surgical Wounds","Early Versus Delayed Bathing of Orthopaedic Surgical Wounds: a Prospective Randomized Controlled Study","EVDB","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Patient who are not pregnant\n* Isolated acute fractures of the upper or lower extremities (humerus, radius, ulna, femur, tibia, or fibula)\n* Diagnosis of a fracture meeting indication for operative intervention\n* Any fracture not requiring a splint for post-operative management\n* Non-complicated wounds (non-traumatic wounds, closed injuries, fractures not requiring external fixation, and acute fracture surgery)\n\nExclusion Criteria:\n\n* Fractures associated with presumed infection\n* Patients with multiple fractures\n* Fractures in patients with underlying associated immune compromise\n* Fractures in patients with underlying peripheral vascular disease\n* Use of VAC\n* Surgery performed through previous surgical wound\n* Patient homeless\n* Fractures in patients with underlying diabetes mellitus\n* Complicated wounds (traumatic wounds, need for post-op wound care, open injuries, need for external fixation)",{"count":46,"type":19},56,"INTERVENTIONAL",[49],"NA","This is a single center randomized control trial assessing the effect of early versus delayed bathing on orthopaedic surgical wounds in patients undergoing surgical treatment of fractures. Patients will be recruited by screening all patients undergoing surgical treatment for fractures at our institution. Patients who provide written consent will be randomized to one of two treatment arms after confirming eligibility criteria. Group A will be advised to begin early normal bathing (non-submerged showering) with uncovered surgical wounds. Group B will be advised to follow traditional delayed bathing with covered wounds.\n\nThose who do not wish to participate in the randomized trial will be invited to participate observationally (no randomization) and have the same prospective follow-up.",[23,52],"Post Operative Wound Infection","2026-03-25",{"date":55,"type":28},"2026-03-30",{"date":57,"type":28},"2024-01-29",{"date":59,"type":19},"2026-12",{"name":61,"class":62},"Hospital for Special Surgery, New York","OTHER",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":15,"minAge":70,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":47,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":36},"100564811","phase-2-evaluating-rhpdgf-bb-enhanced-wound-matrix-for-head-and-neck-reconstruction-100564811","NCT06634030","Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction","A Randomized, Double-Blinded, Controlled Trial Evaluating Recombinant Human Platelet-Derived Growth Factor B (rhPDGF-BB)-Enhanced Wound Matrix in the Reconstruction of Full-Thickness Head or Neck Defects Following Skin Cancer Excision","Inclusion Criteria:\n\n* Underwent surgery to completely remove skin cancer, either Mohs micrographic or wide local excision, that left a full-thickness surgical defect of the head or neck measuring between 1.5-10cm in greatest dimension with clear margins as assessed in the pathology report.\n* Margins of the wound cannot be approximated or closed with stitches, sutures, staples, or glue\n* Surgeon does not plan for immediate skin graft or flap\n* Aged \\>21 years old\n* Willing and able to provide informed consent for study participation and compliance with study protocol\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n* Medical conditions that would, in the opinion of the Investigator or treating provider, compromise the safety of the individual with study participation and\u002For the ability of the individual to follow study protocol\n* The device will not fit the contour of the base of the wound bed\n* Evidence of current clinical infection as demonstrated by the invasion of bacteria into the healthy viable tissue on the periphery of the wound (colonization of wound bed due to normal flora or environment is not exclusionary)\n* Prior radiation therapy at the application site\n* Known allergic reactions to porcine tissue, porcine collagen, or yeast-derived products\n* Currently enrolled in a drug or device trial or within 30 days of last investigational drug or device administration at baseline visit where investigational treatment (drug or device) was placed in wound bed or may potentially interact with study treatment\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial","22 Years",{"count":72,"type":19},40,[74],"PHASE2","Skin cancers such as basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma lesions that develop on the head and neck are treated by Mohs surgery or wide local excision to remove all tumor cells and preserve the normal tissue. These surgical techniques may result in large defects requiring reconstruction to restore function and aesthetics. Rotational flaps and free flaps are techniques used to reconstruct large, complex defects that cannot be closed with sutures, staples, or glue. Older, frail patients are particularly vulnerable to complications from these procedures often leaving them to care for chronic wounds until a skin graft can be placed. Phenome-wide association studies (PheWAS) revealed a cohort of patients with a single nucleotide variant (SNV) in PDGFRβ having a higher incidence of chronic skin ulcers, skin grafts, and other skin and connective tissue disorders suggesting that the loss of PDGFβ signaling may impair healing following trauma. rhPDGF-BB, a recombinant human platelet derived growth factor protein-based therapy, signals through PDGFRβ to mediate inflammation, granulation, angiogenesis, and remodeling during wound healing and skin repair and is FDA cleared for diabetic neuropathic ulcers and periodontal bone and soft tissue reconstructions. These data suggest rhPDGF-BB may be a viable therapeutic strategy to augment the reconstruction of these complex defects by accelerating granulation, epithelialization, and wound closure.",[77,23],"Wound Healing",[79,80,81],"Complex Surgical Defect","Skin Cancer Excision","Platelet-Derived Growth Factor","2026-03-18",{"date":84,"type":28},"2026-03-23",{"date":86,"type":28},"2025-04-01",{"date":88,"type":19},"2026-06",{"name":90,"class":62},"Vanderbilt University Medical Center",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":99,"minAge":16,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":47,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100624386","co2lift-and-t-junction-breakdown-rates-evaluation-after-breast-reduction-surgery-pilot-trial-100624386","NCT07408960","CO2Lift and T-Junction Breakdown Rates Evaluation After Breast Reduction Surgery Pilot Trial","Evaluating the Effect of CO2Lift Pro® Carboxy Gel on T-Junction Breakdown Rates After Breast Reduction Surgery: A Feasibility Study","CO2-BREAST","Inclusion Criteria:\n\n* Female patients aged 18 to 85 years\n* Undergoing bilateral reduction mammoplasty using an inverted-T (Wise pattern) technique\n* American Society of Anesthesiologists (ASA) physical status classification I-III\n* Able and willing to provide informed consent\n* Willing and able to comply with study procedures and follow-up visits\n\nExclusion Criteria:\n\n* Prior radiation therapy to either breast\n* Prior breast reduction surgery to either breast\n* Known allergy or sensitivity to CO2Lift®, Vaseline®, or any of the ingredients\n* Pregnant or breastfeeding\n* History of immunosuppressive therapy\n* History of keloid formation\n* Active local or systemic infection at the time of surgery\n* Current smoker or history of substance abuse (including alcohol or illicit drugs)\n* Use of asymmetrical breast reduction techniques\n* Anticipated inability to complete follow-up or loss to follow-up","FEMALE","85 Years",{"count":102,"type":19},10,[49],"The goal of this pilot study is to determine the feasibility of a larger randomized controlled trial evaluating CO₂Lift® Pro Carboxy Gel to reduce wound breakdown after bilateral breast reduction in adult female patients undergoing elective bilateral breast reduction surgery. The main question it aims to answer is: Is it feasible to recruit, retain, and treat patients while maintaining blinding and monitoring safety?\n\nExploratory questions include: (1) Does CO₂Lift® reduce the incidence of wound breakdown compared with placebo? (2) Is CO₂Lift® safe and well-tolerated in the postoperative period?\n\nResearchers will compare CO₂Lift® applied to one breast to placebo (Vaseline®) applied to the contralateral breast to see if CO₂Lift® can improve wound healing and tissue oxygenation.\n\nParticipants will:\n\n* Undergo bilateral breast reduction surgery.\n* Receive CO₂Lift® on one breast and placebo on the other, starting immediately after surgery and daily in clinic from postoperative days 1 to 6.\n* Attend weekly postoperative follow-up visits for 12 weeks for wound assessment and monitoring of adverse events.\n* Have standardized photographs and near-infrared spectroscopy measurements taken to evaluate tissue oxygenation and healing.",[106,107,23,108],"Wound Breakdown","Breast Reduction","Breast Surgery","NOT_YET_RECRUITING","2026-02-10",{"date":112,"type":28},"2026-02-13",{"date":114,"type":19},"2026-04-01",{"date":116,"type":19},"2027-12-31",{"name":118,"class":62},"University of Calgary",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":47,"phases":129,"briefSummary":130,"conditions":131,"keywords":138,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100620637","muscle-damage-of-the-tfl-tensor-fascia-latae-during-total-hip-arthroplasty-tha-through-direct-anterior-approach-daa-100620637","NCT07360210","Muscle Damage of the TFL (Tensor Fascia Latae) During Total Hip Arthroplasty (THA) Through Direct Anterior Approach (DAA)","Muscle Damage of the TFL (Tensor Fascia Latae) During Total Hip Arthroplasty (THA) Through Direct Anterior Approach (DAA), Evaluation of the Correlation With Short Term Functional Results","TFL","Inclusion Criteria:\n\n* adult (\\>18 years old),\n* patient undergoing primary Total Hip Arthroplasty through Direct Anterior Approach for osteoarthritis\n\nExclusion Criteria:\n\n* hip dysplasia\n* leg length discrepancy greater than 2cm\n* history of homolateral hip surgery\n* neuromuscular pathology\n* patients declining the protocol",{"count":128,"type":19},150,[49],"Direct Anterior Approach (DAA) is known to cause damage to the TFL during the surgical approach, the point of this study is to evaluate the impact between the severity of the per operative TFL damage and the functional short term results.",[132,133,134,135,23,136,137],"Hip Joint","Surgery","Arthroplasty","Replacement","Muscle Injury","Fascia Lata",[139,140],"TFL damage","Total Hip Arthroplasty through Direct Anterior Approach","2026-01-14",{"date":143,"type":28},"2026-01-22",{"date":145,"type":19},"2026-02",{"date":147,"type":19},"2026-10",{"name":149,"class":62},"University Hospital, Bordeaux",2,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":158,"sex":15,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":163,"conditions":164,"keywords":172,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":36},"100396242","fmri-and-ivcm-cornea-microscopy-of-cxl-in-keratoconus-100396242","NCT04439552","fMRI and IVCM Cornea Microscopy of CXL in Keratoconus","Neuroplasticity of Pain Pathways and Corneal Afferent Regeneration Following Corneal Crosslinking (CXL) in Keratoconus","Inclusion Criteria:\n\nCXL Group\n\n* Age 8-35 years\n* Clinical diagnosis of keratoconus and seeking CXL treatment\n* English speaking ability sufficient to comprehend consent with parental assistance\n* MRI compatible\n* Ability to lie still for an MRI session (60 minutes)\n\nControl Group\n\n* Age 8-35 years\n* No diagnosis of keratoconus\n* English speaking ability sufficient to comprehend consent with parental assistance\n* MRI compatible\n* Ability to lie still for an MRI session (60 minutes)\n\nExclusion Criteria (Both Groups):\n\n* Claustrophobic\n* Weight \\> 285 lbs (weight limit of the MRI table)\n* Significant medical history, including:\n\nCurrent DSM-IV-TR axis I psychiatric disorders. Chronic pain Significant head injury Seizures Brain tumor Cerebrovascular accident Neurological disease aside from migraine HIV-AIDs Prescription medication strongly implicated in causing dry eyes\n\n* Magnetic implants or metal-containing tattoos on their chest or above\n* Pregnancy\n* History of contact lens wear\n* Any allergic response to a numbing eyedrop in the past",true,"8 Years","35 Years",{"count":162,"type":19},60,"Evaluation of neuroplasticity of pain pathways and corneal afferent nerve regeneration following corneal crosslinking (CXL) in keratoconus patients using fMRI and corneal In Vivo Confocal Microscopy (IVCM).",[165,166,167,168,23,169,170,171],"Pain, Postoperative","Pain, Chronic","Pain, Acute","Surgical Injury","Cornea Injury","Cornea","Keratoconus",[173,174,175,176],"fMRI","Corneal Microscopy","IVCM","Neuroimaging","2025-12-15",{"date":179,"type":28},"2025-12-19",{"date":181,"type":28},"2021-10-04",{"date":183,"type":19},"2027-12",{"name":185,"class":62},"Boston Children's Hospital",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":158,"sex":15,"minAge":16,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":47,"phases":196,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":206,"locationsCount":36},"100536021","phase-1-regenn-therapy-system-safety-study-100536021","NCT06259409","Regenn® Therapy System Safety Study","A Randomized Clinical Study Evaluating the Safety of Regenn® Negative Pressure Therapy System in Orthopaedic Surgical Wound Management","Inclusion Criteria (must meet ALL):\n\n* Subject has provided written informed consent on a form reviewed and approved by the Institutional Review Board for the clinical site.\n* The subject is 18 - 80 years old.\n* The subject has Spondylolisthesis of Meyerding Grade II or less, or has Degenerative Disc Disease (DDD) accompanied by back pain with or without leg pain at a level between L1 and S1 confirmed by history and radiographic assessment. DDD is determined to be present if one or more of the following are noted:\n\n  * Instability (defined as angulation ≥ 5 degrees and\u002For translation ≥ 3mm on flexion\u002Fextension radiographs;\n  * Osteophyte formation of facet joints or vertebral endplates;\n  * Decreased disc height, on average by \\>2mm, but dependent upon the spinal level;\n  * Scarring \u002F thickening of ligamentum flavum, annulus fibrosis, or facet joint capsule;\n  * Herniated nucleus pulposus;\n  * Facet joint degeneration \u002F changes; and\u002For\n  * Vacuum phenomenon.\n* Female subjects of childbearing potential must not be pregnant or nursing and must agree to use of contraception for the study duration. Female subjects who are surgically sterile or post-menopausal are exempt from having a pregnancy test and birth control.\n* The subject is willing and able to comply with the protocol mandated follow-up visits and testing regimen.\n\nExclusion Criteria (candidates meeting ANY of the following at the time of the study procedure are NOT eligible):\n\n* Subject is unable or unwilling to provide informed consent or is unable to conform to the study protocol follow-up procedures and visits.\n* Subject has a contraindication (including allergic reaction) to antiplatelet\u002Fanticoagulant medications, nickel, titanium, bone allograft, or blood transfusion that is not amenable to pretreatment with steroids or\u002Fand antihistamines.\n* Subject has a history of bleeding diatheses or coagulopathy.\n* Subject has concomitant hepatic insufficiency, thrombophlebitis, uremia, systemic lupus erythematosus (SLE), or any autoimmune diseases.\n* Subject is receiving dialysis or immunosuppressive therapy.\n* Subject suffered a hemorrhagic stroke \\\u003C 6 months prior to the study procedure.\n* Subject is undergoing spinal surgery for vertebral fracture, trauma, or scoliosis.\n* Subject has any form of active malignancy.\n* Subject is an intravenous drug user and\u002For alcoholic.\n* Subject is diagnosed with septicemia at the time of the study procedure.\n* Subject is a smoker.\n* Subject has Type I diabetes.\n* Subject has overt, uncontrolled Type II diabetes.\n* Subject has a condition requiring postoperative medications that would be expected to interfere with fusion (e.g., steroids), or has received drugs that interfere with bone metabolism within 2 weeks of the surgery.\n* Subject is suffering from gross obesity, defined as \\> 40% IBW.\n* Subject exhibits Waddell signs of Inorganic Behavior ≥ 3.\n* Subject has had a previous, anterior spinal fusion, interbody spinal fusion, or posterior spinal instrumentation at the involved level.\n* Subject has another medical condition, which may cause them to be non-compliant with the protocol, confound the data interpretation, or is associated with limited life expectancy of less than two years.\n* Subject has a systemic disease of connective tissue such as Rheumatoid Arthritis, or Ankylosing Spondylitis.\n* Subject is a prisoner.\n* Subject is currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials).","80 Years",{"count":195,"type":19},30,[197],"PHASE1","The goal of this clinical trial is to evaluate the safety of the investigational device, Regenn® Negative Pressure Therapy System (Regenn® Therapy), a form of Negative Pressure Wound Therapy (NPWT), in the post-operative surgical wounds of patients undergoing lumbar spinal fusion surgeries. The main questions the study aims to answer are:\n\n* The device-related serious adverse event rate.\n* Patient post-operative pain as assessed using a validated pain measurement scoring system.\n* The number and type of adverse events.\n* The rate of delayed seroma formation.\n\nParticipants will\n\n* Be screened for their suitability to participate in the investigational study using questions about their health, medical history, and current medications.\n* Undergo a physical exam, an assessment of patient vital signs and routine blood analyses.\n* Complete an Informed Consent Form if selected to participate in the investigational study.\n* Be randomly assigned to the different study arms.\n* Not change the operation of their respective device or to disturb components of their device.\n* Notify their surgeon or designated healthcare provider should they have any questions or encounter any issues with their device.\n* Attend two post-operative visits at approximately one month and three months.",[23],"2025-09-08",{"date":202,"type":28},"2025-09-15",{"date":204,"type":28},"2024-10-09",{"date":88,"type":19},{"name":207,"class":35},"Progenerative Medical, Inc",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":158,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":47,"phases":216,"briefSummary":218,"conditions":219,"keywords":225,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":36},"100328836","early-phase-1-zinc-oxide-versus-petrolatum-following-skin-surgery-100328836","NCT03561376","Zinc Oxide Versus Petrolatum Following Skin Surgery","Zinc Oxide Versus Petrolatum Following Skin Surgery: A Head-to-head, Prospective, Split-scar Study","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Linear closure, non-scalp site\n3. ≥ 4.5 cm in length (final incision\u002Fclosure length)\n4. End to end symmetry (surgical site is not grossly asymmetric from end to end)\n5. Grossly uninfected site\n\nExclusion Criteria:\n\n1. ≤ 18 years\n2. Visibly asymmetric linear scar\n3. Grossly infected surgical site\n4. History of allergy to topical zinc oxide",{"count":195,"type":19},[217],"EARLY_PHASE1","Patients undergoing routine surgery in the Department of Dermatology for any indication on non-scalp skin and closed in linear fashion with scar greater than or equal to 4.5cm in length will be invited to participate in this split scar, head to head study comparing zinc oxide and petrolatum. Patients will apply respective ointments to each half of scar daily for one month and maintain a log of these activities. They will be seen at 1 week, 4 weeks, 8 weeks, and 6 months post-operatively for photographic scar assessment and to complete the patient portion of the Patient and Observer Scar Assessment Scale (POSAS), a quantitative objective assessment of scar appearance. Trained observers (board-certified dermatologists) will score the observer portion of the scale. POSAS outcomes, post-operative infections, linear density of epidermal seal will be assessed at the 1 week, 4 weeks, 8 weeks, and 6 months post-operative periods and compared between the two groups. Participants will have parking validated for all visits and upon completion of all portions of the study will receive a standardized skin care gift bag containing samples for hypoallergenic skin care products (washes, moisturizers, etc.).",[220,221,23,222,223,224],"Surgical Incision","Surgery--Complications","Surgical Site Infection","Scar","Hypertrophic Scar",[223],"2025-08-12",{"date":228,"type":28},"2025-08-14",{"date":230,"type":28},"2021-09-01",{"date":232,"type":19},"2026-10-30",{"name":234,"class":62},"Melissa Pugliano-Mauro",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":47,"phases":245,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":36},"100515275","phase-2-outcomes-of-high-volume-saline-irrigation-vs-povidone-iodine-solution-cleaning-of-iowi-in-preventing-ssis-in-emergency-laparotomies-100515275","NCT05989386","Outcomes of High-volume Saline Irrigation VS Povidone-Iodine Solution Cleaning of IOWI in Preventing SSIs in Emergency Laparotomies","Outcomes of High-volume Saline Irrigation VS Povidone-Iodine Solution Cleaning of Intraoperative Incision Wound in Preventing Surgical Site Infections in Emergency Laparotomies: A Randomized Controlled Trial","Inclusion Criteria:\n\n* • Patients undergoing emergency laparotomy under the care of surgical-6 unit of Dr. Ruth K. M. Pfau Civil Hospital Karachi\n\n  * The age of patients should be between 18-60 years old.\n\nExclusion Criteria:\n\n* Diabetic patients\n* Immune-suppressed patients\n* Patients taking steroids\n* Patients undergoing chemo-radiotherapy.\n* Pregnant females\n* Previous abdominal surgery within the last 30 days.\n* Presence of concurrent abdominal wall infections.\n* Trauma Laparotomies\n* Large Bowel perforations","60 Years",{"count":244,"type":19},200,[74,246],"PHASE3","The goal of this clinical trial is to compare the outcomes of High-volume saline irrigation vs Povidone-iodine solution cleaning of the intraoperative incision wound in preventing superficial surgical site infections in patients undergoing emergency laparotomies. The main question it aims to answer are:\n\n* Incidence of SSI after intervention\n* Length of hospital stay\n\nParticipants will be randomly assigned to two groups receiving either of the two groups:\n\nGroup A: 1000ml of IOWI with saline solution prior to incision closure Group B: The incisional wound will be closed conventionally without irrigation.\n\nResearchers will compare groups A( experimental group) and B (control group) to compare the incidence of superficial surgical site infections after intervention.",[222,23,220,249,250,52,251,252],"Emergency Laparotomies","Laparotomies","Wound Infection","Seroma","2025-06-14",{"date":255,"type":28},"2025-06-18",{"date":257,"type":28},"2023-04-29",{"date":259,"type":19},"2025-12-29",{"name":261,"class":62},"Dow University of Health Sciences",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":47,"phases":270,"briefSummary":271,"conditions":272,"keywords":273,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":36},"100586039","use-of-fish-skin-graft-fsg-to-improve-wound-healing-and-expedite-discharge-at-a-county-safety-net-hospital-100586039","NCT06910189","Use of Fish Skin Graft (FSG) to Improve Wound Healing and Expedite Discharge at a County Safety-net Hospital","Inclusion Criteria:\n\n* Has wound greater than or equal to 40cm2 requiring surgical debridement\n* Agreeable to follow up period of up to 1 year\n\nExclusion Criteria:\n\n* Patients with wounds that do not require surgical debridement.\n* Patients with a known allergy or other sensitivity to fish material\n* Patients who are deemed unlikely to follow up (e.g., patients who live out of state).\n* Patients in police custody\u002Fincarcerated.\n* Patients unable to communicate in either Spanish or English.",{"count":269,"type":19},96,[49],"The purpose of this study is to estimate the effect of FSG (Kerecis) on hospital length of stay among adult patients with surgical wounds of at least 40cm2 requiring surgical debridement",[23],[274,275],"Fish Skin Graft (FSG)","Kerecis","2025-03-27",{"date":278,"type":28},"2025-04-04",{"date":280,"type":19},"2025-04-15",{"date":282,"type":19},"2026-11-30",{"name":284,"class":62},"The University of Texas Health Science Center, Houston",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":100,"enrollmentInfo":291,"targetDuration":4,"studyType":47,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":304,"locationsCount":4},"100554770","a-prospective-study-using-suprasdrm-in-promoting-healing-and-reducing-the-time-to-grafting-of-full-thickness-wounds-100554770","NCT06503406","A Prospective Study Using SupraSDRM® in Promoting Healing and Reducing the Time to Grafting of Full-thickness Wounds","Inclusion Criteria:\n\n* Patient age ≥18 years and ≤85 years\n* Full-thickness traumatic injury, surgical wound, or excised full-thickness burn (e.g., friction, contact, flame, scalding etiology), where immediate grafting is not deemed suitable by the treating surgeon\n* Wound size ≥ 5cm2 not immediately suitable for graft application\n* Subject or legally authorized representative is able and willing to sign informed consent\n\nExclusion Criteria:\n\n* Study wound may not include areas of the face, and neck and genitalia.\n* Wound with metal hardware exposure\n* Pressure sores\n* Wounds with residual malignancy\n* Wound infection at the time of planned wound dressing application\n* Wound that is a part of an active treatment arm of an interventional study (within 90 days of Screening Visit)\n* Pregnancy\u002Flactation\n* Subjects who are unable to follow the protocol or who are likely to be non-compliant\n* Subjects with uncontrolled diabetes (defined by Hgb A1C \\>10)\n* Subjects who are receiving systemic steroids or immune suppressive treatment\n* Subject with a known allergy to polylactide, polycaprolactone, polyvinyl alcohol, trimethylene carbonate or resorbable suture materials.\n* Prisoners",{"count":292,"type":19},24,[49],"This is a prospective, randomized, controlled, multi-center clinical study comparing SupraSDRM® to standard of care wound dressing, BTM, in the treatment of full-thickness wounds deemed not immediately suitable for definitive grafting will be performed.",[23,296,297],"Burns","Trauma Injury","2025-02-19",{"date":300,"type":28},"2025-02-21",{"date":302,"type":19},"2025-03",{"date":147,"type":19},{"name":305,"class":62},"The Metis Foundation",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":15,"minAge":313,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":47,"phases":315,"briefSummary":316,"conditions":317,"keywords":321,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":36},"100368594","oasis-donor-site-wounds-post-market-study-100368594","NCT04079348","Oasis Donor Site Wounds Post-Market Study","Feasibility Study to Compare OASIS Extracellular Matrix to Standard Wound Care for Treatment of Donor Site Wounds","Inclusion Criteria:\n\n1. Has a split thickness skin graft (STSG) donor site wound no greater than 14 x 20 cm in size requiring placement of a covering material.\n2. Has at least 24 hours to consent to study participation.\n\nExclusion Criteria:\n\n1. Age \\\u003C 16 years\n2. Patients who, in the opinion of the investigator, have co-morbidities that impair wound healing, such as:\n\n   1. Chronic inflammatory skin condition\n   2. Chronic liver failure\n   3. Chronic renal failure\n   4. Blood-borne viruses (Hep B, Hep C, HIV)\n   5. Peripheral vascular disease\n   6. Clinically significant anaemia\n   7. Uncontrolled diabetes\n3. Need for use of the same harvest site (re-cropping)\n4. History of radiation therapy to proposed donor site\n5. Chronic use of medications known to impair wound healing\n6. Chronic use of opioids or neuropathic pain agents\n7. Suspected cellulitis, osteomyelitis or septicaemia\n8. Patients undergoing haemodialysis\n9. Patients requiring spinal\u002Fregional block\n10. Patients on current anti-coagulant therapy\n11. Unable or unwilling to provide informed consent\n12. Unable or unwilling to comply with the study follow-up schedule, and procedures\n13. Simultaneously participating in another investigational drug or device study (patient must have completed the follow-up phase for the primary endpoint of any previous study at least 30 days prior to enrolment in this study)\n14. Allergy or hypersensitivity to materials that are porcine-based\n15. Cultural or religious objection to the use of pig or porcine products\n16. Known intolerance\u002Fallergy to standard wound care products\n17. Presence of a local infection at the donor site and\u002For systemic infection","16 Years",{"count":72,"type":19},[49],"The purpose of this study is to demonstrate the safety and performance of Oasis extracellular matrix (ECM) when used as a treatment for donor site wounds in the United Kingdom. Oasis ECM is commercially available for the treatment of partial and full-thickness skin wounds, including chronic wounds, wounds from trauma, and wounds that occur during surgery, such as donor site wounds. The ability of the Oasis ECM to promote the healing of donor site wounds will be evaluated in this study.\n\nAbout 40 patients (20 in each arm) over 16 years old will be involved in this study at one center in the United Kingdom.",[23,318,319,320],"Wound","Wounds and Injuries","Wound Heal",[322],"Donor Site Wound","2024-12-12",{"date":325,"type":28},"2024-12-17",{"date":327,"type":28},"2020-11-01",{"date":329,"type":19},"2025-12",{"name":331,"class":35},"Cook Biotech Incorporated",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":47,"phases":341,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":4},"100552686","virtual-reality-glasses-and-stress-ball-applications-in-dressing-change-100552686","NCT06476314","Virtual Reality Glasses and Stress Ball Applications in Dressing Change","Examination of the Effects of Virtual Reality Glasses and Stress Ball Applications on Pain, Vital Signs Anxiety, Fear, Satisfaction, and Comfort Levels During the Dressing Changes in Patients Who Underwent Abdominal Surgery","Inclusion Criteria:\n\n* Acceptance to participate in the study both in writing and verbally.\n* Being over 18,\n* Having undergone abdominal surgery,\n* Being on the 1st day after surgery,\n* Being subjected to first dressing after surgery,\n* Staying in the one-person room or being the only patient in the room,\n* Being conscious (person, place and time orientation),\n* Patients who have no vision, hearing or communication problems will be included in the study.\n\nExclusion Criteria:\n\n* Patients using analgesic, anxiolytic, and sedative medications before, during, and immediately after dressing changes.\n* Having chronic pain disorder\n* Having a disease that may affect primarily vital signs (such as Hypertension, COPD),\n* Not having any psychiatric and cognitive\u002Fmental disease (dementia, etc.),\n* Having chronic diseases like epilepsy, vertigo,\n* Being diagnosed with vision, hearing(auditory) and\u002For balance disorder\n* Having an addiction or abusing alcohol or drugs.",{"count":340,"type":19},120,[49],"According to the statistical data of the Ministry of Health for the year 2021 in Türkiye, approximately 4.7 million surgical interventions are performed annually. According to the 2017 data from the National Health Service-Associated Infections Surveillance Network, the Surgical Site Infection (SSI) rate in our country is 0.72%, and it is stated that it can be prevented by approximately 60%. Dressing application holds an important place in surgical wound management, wound healing, and preventing complications. Patients may experience pain, anxiety, and fear due to unknown factors and previous experiences during the dressing change which holds an important place in wound care management. The aim is to minimize patients\\' negative emotions\u002Fsituations during dressing changes by diverting their attention elsewhere using virtual reality (VR) glasses and stress balls. Upon reviewing the literature, no study was found that examines the effect of applying VR glasses and stress balls during abdominal surgery dressing changes on pain, vital signs, anxiety, fear, comfort, and satisfaction levels in adults. In this regard, the aim of the research is; to examine the effects of VR glasses and stress ball application on pain, vital signs, anxiety, fear, comfort, and satisfaction levels during dressing changes in patients undergoing abdominal surgery. The study was designed as a pre-test post-test control group randomized experimental model. The sample of the study consists of adult patients who underwent abdominal surgery in Isparta City Hospital General Surgery Service-1. In the study sample, 120 individuals were included in total 40 with VR glasses, 40 individuals using stress balls, and 40 in the control group. Patient Information Form, Visual Analog Scale, and State-Trait Anxiety Scale will be used in data collection. Data from the study will be analyzed with number, percent, average, x-square, variance, and t-test in a computer environment. In consideration of the data, it is believed that important findings will be obtained in increasing satisfaction and comfort by eliminating pain, anxiety, and fear during dressing changes in patients.",[23,344],"Abdominal Surgery",[346,347,348,349,350,351,352,353,354,355,356,357],"Dressing","surgical wound","incision","virtual reality glasses","stress ball","nursing care","pain","vital signs","anxiety","fear","satisfaction","comfort levels","2024-06-20",{"date":360,"type":28},"2024-06-26",{"date":362,"type":19},"2024-07",{"date":364,"type":19},"2025-01",{"name":366,"class":62},"Suleyman Demirel University",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":158,"sex":15,"minAge":374,"maxAge":193,"enrollmentInfo":375,"targetDuration":4,"studyType":47,"phases":377,"briefSummary":378,"conditions":379,"keywords":381,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":4},"100548965","effect-of-topical-tranexamic-acid-on-postoperative-drainage-in-minimally-invasive-transforaminal-lumbar-interbody-fusion-mi-tlif-100548965","NCT06427850","Effect of Topical Tranexamic Acid on Postoperative Drainage in Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI-TLIF)","Effect of Topical Tranexamic Acid on Postoperative Drainage in Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI-TLIF): A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 30-80 years old\n* Degenerative spine problems including spinal stenosis, disc degeneration, spondylolithesis that indicated for single level MI-TLIF\n\nExclusion Criteria:\n\n* Revision surgery\n* Patients who had high risk of complication from TXA\n* History of seizure, PE, DVT, thromboembolic episode\n* History of TXA allergy\n* Patients who had high risk for bleeding\n* U\u002FD : CKD stage more than IIIb (GFR\\\u003C 45 ml\u002Fmin\u002F1.73m2), hepatic disease, bleeding disorder\n* On anticoagulation drug or antiplatelet drug in 7 days before surgery\n* Abnormal coagulation profile (INR \\> 1.5) or CBC (platelet \\\u003C 100000)","30 Years",{"count":376,"type":19},28,[49],"The randomized controlled study which compare the efficacy outcomes (reducing blood loss and drainage output in patients) in patients undergoing single-level minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) and received topical tranexamic acid injection in the surgical site to those who received placebo injection.",[380,23],"Degenerative Spine Diseases",[382,383,384],"Degenerative spine diseases","Surgical wound","Tranexamic acid (TXA)","2024-05-20",{"date":387,"type":28},"2024-05-24",{"date":389,"type":19},"2024-07-01",{"date":391,"type":19},"2026-12-01",{"name":393,"class":62},"Thanawan Longsuwan",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":47,"phases":403,"briefSummary":404,"conditions":405,"keywords":406,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":36},"100469177","pico-7-vs-pico-14-in-revision-hip-and-revision-knee-surgery-100469177","NCT05389410","PICO 7 vs PICO 14 in Revision Hip and Revision Knee Surgery.","Comparison of Surgical Wound Healing and Complications Following Revision Hip and Knee Replacements, Utilising a 7-day Versus 14-day Negative Pressure Wound Therapy (NPWT) Dressing. A Randomised Controlled Trial.","Inclusion Criteria:\n\n* Subjects must be over the age of 18 years.\n* Participants undergoing aseptic revision hip or aseptic revision knee surgery procedure (a single stage revision procedure).\n* Participants must be willing and be able to make all the required study visits to be seen by the research team at the Outpatients department at RJAH.\n* Participants must be able to follow instructions.\n\nExclusion Criteria:\n\n* Revisions for infection, where the nature of the infection has a significant influence on the wound healing, discharge, and length of stay.\n* Subjects with a history of poor compliance with medical treatment.\n* Subjects with contraindications (as per the PICO Instructions for use) or hypersensitivity to the use of the NPWT PICO dressing product or its components e.g.: silicone adhesives, polyurethane films, acrylic adhesives, polyethylene fabrics and super- absorbent powders (polyacrylates) contained within the dressing.",{"count":402,"type":19},164,[49],"This is a single-site trial, and it has been designed to compare a revision hip cohort with a revision knee cohort. All consecutive eligible patients, under the care of participating Co-Investigator Orthopaedic Surgeons, are approached for recruitment into the study.\n\nEligible patients wishing to participate must require either revision hip or revision knee surgery and consent to be randomised to either NPWT PICO dressing for 7-day therapy (PICO 7) or NPWT PICO 14-day therapy (PICO 14).\n\n82 Revision Hips and 82 Revision Knee participants, with 41\\* of each cohort randomised to either a 7-day or a 14-day NPWT dressing treatment duration period. The 7-day cohort will be treated with PICO7 dressings and pumps, and the 14-day cohort will be treated with PICO14 dressings.\n\n\\*Randomisation will be stratified, so it will continue until there are at least 41 participants in each cohort.",[23],[407],"Revision hip and revision knee surgery","2024-03-21",{"date":410,"type":28},"2024-03-25",{"date":412,"type":28},"2024-02-14",{"date":414,"type":19},"2027-02-14",{"name":416,"class":417},"Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust","OTHER_GOV"]